{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:41:43Z","timestamp":1790228503502,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T00:00:00Z","timestamp":1519603200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A., Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s10620-018-4971-1","type":"journal-article","created":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T10:22:36Z","timestamp":1519640556000},"page":"825-833","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease"],"prefix":"10.1007","volume":"63","author":[{"given":"Mark","family":"Fleisher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Marsal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Frado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Parian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burton I.","family":"Korelitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Feagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,26]]},"reference":[{"key":"4971_CR1","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1097\/MIB.0000000000000661","volume":"22","author":"PS Dulai","year":"2016","unstructured":"Dulai PS, Singh S, Casteele NV, Boland BS, Sandborn WJ. How will evolving future therapies and strategies change how we position the use of biologics in moderate to severely active inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:998\u20131009.","journal-title":"Inflamm Bowel Dis"},{"key":"4971_CR2","doi-asserted-by":"publisher","first-page":"2097274","DOI":"10.1155\/2016\/2097274","volume":"2016","author":"FA Silva","year":"2016","unstructured":"Silva FA, Rodrigues BL, Ayrizono ML, Leal RF. The immunological basis of inflammatory bowel disease. Gastroenterol Res Pract. 2016;2016:2097274.","journal-title":"Gastroenterol Res Pract"},{"issue":"351\u2013361","key":"4971_CR3","first-page":"e355","volume":"152","author":"JF Colombel","year":"2017","unstructured":"Colombel JF, Narula N, Peyrin-Biroulet L. Management strategies to improve outcomes of patients with inflammatory bowel diseases. Gastroenterology. 2017;152(351\u2013361):e355.","journal-title":"Gastroenterology"},{"key":"4971_CR4","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1053\/j.gastro.2013.07.041","volume":"145","author":"AD Frolkis","year":"2013","unstructured":"Frolkis AD, Dykeman J, Negron ME, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013;145:996\u20131006.","journal-title":"Gastroenterology"},{"key":"4971_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/gastro\/gou087","volume":"3","author":"AC Moss","year":"2015","unstructured":"Moss AC. Optimizing the use of biological therapy in patients with inflammatory bowel disease. Gastroenterol Rep (Oxf). 2015;3:63\u201368.","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"4971_CR6","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","volume":"362","author":"JF Colombel","year":"2010","unstructured":"Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease. N Engl J Med. 2010;362:1383\u20131395.","journal-title":"N Engl J Med"},{"key":"4971_CR7","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cgh.2013.06.019","volume":"12","author":"JF Colombel","year":"2014","unstructured":"Colombel JF, Rutgeerts PJ, Sandborn WJ, et al. Adalimumab induces deep remission in patients with Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2014;12:414\u2013422.e5.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4971_CR8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S1873-9954(07)70190-8","volume":"1","author":"S Schreiber","year":"2007","unstructured":"Schreiber S, Reinisch W, Colombel JF, et al. P178 early Crohn\u2019s disease shows high levels of remission to therapy with adalimumab: sub-analysis of CHARM. J Crohn\u2019s Colitis Suppl. 2007;1:49.","journal-title":"J Crohn\u2019s Colitis Suppl"},{"key":"4971_CR9","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/ajg.2015.233","volume":"110","author":"L Peyrin-Biroulet","year":"2015","unstructured":"Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): Determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324\u20131338.","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 1","key":"4971_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000341950","volume":"86","author":"PL Lakatos","year":"2012","unstructured":"Lakatos PL, Lakatos L, Kiss LS, Peyrin-Biroulet L, Schoepfer A, Vavricka S. Treatment of extraintestinal manifestations in inflammatory bowel disease. Digestion. 2012;86(Suppl 1):28\u201335.","journal-title":"Digestion"},{"key":"4971_CR11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","volume":"10","author":"M Harbord","year":"2016","unstructured":"Harbord M, Annese V, Vavricka SR, et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10:239\u2013254.","journal-title":"J Crohns Colitis"},{"key":"4971_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/0016-5085(94)90066-3","volume":"107","author":"S Bhagat","year":"1994","unstructured":"Bhagat S, Das KM. A shared and unique peptide in the human colon, eye, and joint detected by a monoclonal antibody. Gastroenterology. 1994;107:103\u2013108.","journal-title":"Gastroenterology"},{"key":"4971_CR13","first-page":"235","volume":"7","author":"JS Levine","year":"2011","unstructured":"Levine JS, Burakoff R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Hepatol (NY). 2011;7:235\u2013241.","journal-title":"Gastroenterol Hepatol (NY)"},{"key":"4971_CR14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1136\/gut.42.3.387","volume":"42","author":"TR Orchard","year":"1998","unstructured":"Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut. 1998;42:387\u2013391.","journal-title":"Gut"},{"key":"4971_CR15","first-page":"173","volume":"24","author":"PV Voulgari","year":"2011","unstructured":"Voulgari PV. Rheumatological manifestations in inflammatory bowel disease. Ann Gastroenterol. 2011;24:173\u2013180.","journal-title":"Ann Gastroenterol"},{"key":"4971_CR16","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.3748\/wjg.15.2469","volume":"15","author":"F Atzeni","year":"2009","unstructured":"Atzeni F, Ardizzone S, Bertani L, Antivalle M, Batticciotto A, Sarzi-Puttini P. Combined therapeutic approach: inflammatory bowel diseases and peripheral or axial arthritis. World J Gastroenterol. 2009;15:2469\u20132471.","journal-title":"World J Gastroenterol"},{"key":"4971_CR17","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D Heijde van der","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54:2136\u20132146.","journal-title":"Arthritis Rheum"},{"key":"4971_CR18","doi-asserted-by":"publisher","first-page":"S465","DOI":"10.1038\/ajg.2009.518","volume":"104","author":"D Schwartz","year":"2009","unstructured":"Schwartz D, Lofberg R, Pollack P. Adalimumab-treated patients with moderate to severe Crohn\u2019s disease experienced reductions in extraintestinal manifestations data from CHARM. Am J Gastroenterol. 2009;104:S465.","journal-title":"Am J Gastroenterol"},{"key":"4971_CR19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.12998\/wjcc.v1.i2.74","volume":"1","author":"M Zippi","year":"2013","unstructured":"Zippi M, Pica R, De Nitto D, Paoluzi P. Biological therapy for dermatological manifestations of inflammatory bowel disease. World J Clin Cases. 2013;1:74\u201378.","journal-title":"World J Clin Cases"},{"key":"4971_CR20","doi-asserted-by":"publisher","first-page":"4802","DOI":"10.3748\/wjg.v22.i20.4802","volume":"22","author":"M Principi","year":"2016","unstructured":"Principi M, Cassano N, Contaldo A, et al. Hydradenitis suppurativa and inflammatory bowel disease: an unusual, but existing association. World J Gastroenterol. 2016;22:4802\u20134811.","journal-title":"World J Gastroenterol"},{"key":"4971_CR21","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/j.1365-2133.1996.tb03826.x","volume":"135","author":"GJ Nevitt","year":"1996","unstructured":"Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients\u2019 beliefs and attitudes towards the disease. Br J Dermatol. 1996;135:533\u2013537.","journal-title":"Br J Dermatol"},{"key":"4971_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/annrheumdis-2013-203582","volume":"74","author":"C Stolwijk","year":"2015","unstructured":"Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:65\u201373.","journal-title":"Ann Rheum Dis"},{"key":"4971_CR23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/00005792-197609000-00004","volume":"55","author":"AJ Greenstein","year":"1976","unstructured":"Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn\u2019s disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore). 1976;55:401\u2013412.","journal-title":"Medicine (Baltimore)"},{"key":"4971_CR24","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1111\/j.1572-0241.2001.03756.x","volume":"96","author":"CN Bernstein","year":"2001","unstructured":"Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96:1116\u20131122.","journal-title":"Am J Gastroenterol"},{"key":"4971_CR25","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1097\/MIB.0000000000000392","volume":"21","author":"SR Vavricka","year":"2015","unstructured":"Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2015;21:1982\u20131992.","journal-title":"Inflamm Bowel Dis"},{"key":"4971_CR26","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1136\/gut.2005.074815","volume":"55","author":"TN Brooklyn","year":"2006","unstructured":"Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55:505\u2013509.","journal-title":"Gut"},{"key":"4971_CR27","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0016-5085(67)80103-3","volume":"52","author":"BI Korelitz","year":"1967","unstructured":"Korelitz BI, Coles RS. Uveitis (iritis) associated with ulcerative and granulomatous colitis. Gastroenterology. 1967;52:78\u201382.","journal-title":"Gastroenterology"},{"key":"4971_CR28","doi-asserted-by":"publisher","first-page":"4819","DOI":"10.3748\/wjg.v12.i30.4819","volume":"12","author":"KS Rothfuss","year":"2006","unstructured":"Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol. 2006;12:4819\u20134831.","journal-title":"World J Gastroenterol"},{"key":"4971_CR29","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1509852","volume":"375","author":"GJ Jaffe","year":"2016","unstructured":"Jaffe GJ, Dick AD, Brezin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375:932\u2013943.","journal-title":"N Engl J Med"},{"key":"4971_CR30","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","volume":"10","author":"T Wyant","year":"2016","unstructured":"Wyant T, Fedyk E, Abhyankar B. An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis. 2016;10:1437\u20131444.","journal-title":"J Crohns Colitis"},{"key":"4971_CR31","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/j.dld.2016.08.122","volume":"48","author":"PA Pijls","year":"2016","unstructured":"Pijls PA, Gilissen LP. Vedolizumab is an effective alternative in inflammatory bowel disease patients with anti-TNF-alpha therapy-induced dermatological side effects. Dig Liver Dis. 2016;48:1391\u20131393.","journal-title":"Dig Liver Dis"},{"key":"4971_CR32","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699\u2013710.","journal-title":"N Engl J Med"},{"key":"4971_CR33","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2013;369:711\u2013721.","journal-title":"N Engl J Med"},{"key":"4971_CR34","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","volume":"66","author":"JF Colombel","year":"2017","unstructured":"Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease. Gut. 2017;66:839\u2013851.","journal-title":"Gut"},{"key":"4971_CR35","first-page":"S42","volume":"22","author":"D Rubin","year":"2016","unstructured":"Rubin D, Feagan B, Dryden G, et al. The effect of vedolizumab on extraintestinal manifestations in patients with Crohn\u2019s disease in GEMINI 2. Crohn\u2019s Colitis Found Am. 2016;22:S42\u2013S43.","journal-title":"Crohn\u2019s Colitis Found Am"},{"key":"4971_CR36","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.cgh.2016.08.044","volume":"15","author":"BG Feagan","year":"2017","unstructured":"Feagan BG, Rubin DT, Danese S, et al. Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2017;15:229\u2013239.e5.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4971_CR37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cgh.2016.06.025","volume":"15","author":"L Peyrin-Biroulet","year":"2017","unstructured":"Peyrin-Biroulet L, Van Assche G, Gomez-Ulloa D, et al. Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2017;15:25\u201336.e27.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4971_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ibd.21663","volume":"18","author":"R Lofberg","year":"2012","unstructured":"Lofberg R, Louis EV, Reinisch W, et al. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn\u2019s disease: results from CARE. Inflamm Bowel Dis. 2012;18:1\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"4971_CR39","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1111\/j.1572-0241.2003.07581.x","volume":"98","author":"M Regueiro","year":"2003","unstructured":"Regueiro M, Valentine J, Plevy S, Fleisher MR, Lichtenstein GR. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol. 2003;98:1821\u20131826.","journal-title":"Am J Gastroenterol"},{"key":"4971_CR40","doi-asserted-by":"publisher","first-page":"S597","DOI":"10.1016\/S0016-5085(17)32137-6","volume":"152","author":"BG Feagan","year":"2017","unstructured":"Feagan BG, Sandborn WJ, Colombel JF, et al. DOP019 Effect of vedolizumab treatment on extraintestinal manifestations in patients with Crohn\u2019s disease: a GEMINI 2 post hoc analysis. Gastroenterology. 2017;152:S597.","journal-title":"Gastroenterology"},{"key":"4971_CR41","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1136\/annrheumdis-2016-211011","volume":"76","author":"A Orlando","year":"2017","unstructured":"Orlando A, Orlando R, Ciccia F, et al. Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease. Ann Rheum Dis. 2017;76:e31.","journal-title":"Ann Rheum Dis"},{"key":"4971_CR42","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1136\/annrheumdis-2013-203854","volume":"73","author":"L Praet Van","year":"2014","unstructured":"Van Praet L, Jans L, Carron P, et al. Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort. Ann Rheum Dis. 2014;73:1186\u20131189.","journal-title":"Ann Rheum Dis"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-018-4971-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-4971-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-4971-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T17:49:28Z","timestamp":1570816168000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-018-4971-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,26]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["4971"],"URL":"https:\/\/doi.org\/10.1007\/s10620-018-4971-1","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,26]]},"assertion":[{"value":"3 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Feagan has received grant support from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Roche, Genentech, J&J, Janssen, Millennium, Pfizer, Receptos, Tillotts, and UCB and served as a\u00a0consultant or advisory board member for AbbVie, ActoGeniX, Akros, Albireo, Amgen, AstraZeneca, Avaxia Biologics, Avir Pharma, Baxter Healthcare Corp, Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Calypso Biotech, Celgene, Elan\/Biogen, enGene, Ferring Pharmaceuticals, Galapagos, Genentech\/Roche, GiCare Pharma, Gilead, Given Imaging, GSK, Inception IBD Inc, Ironwood Pharmaceuticals, J&J, Janssen, Japan Tobacco, Kyowa Hakko Kirin Co Ltd, Lexicon, Lilly, Lycera Biotech, Merck, Mesoblast Ltd, Millennium, Nektar, Nestl\u00e9, Novartis, Novo Nordisk, Pfizer, Prometheus Therapeutics & Diagnostics, Protagonist, Receptos, Salix, Shire, Sigmoid Pharma, Synergy Pharmaceuticals Inc, Takeda, Teva Pharmaceutical Industries Ltd, TiGenix, Tillotts, UCB Pharma, Vertex Pharmaceuticals, VHsquared Ltd, Warner Chilcott, Wyeth, Zealand Pharma, and Zyngenia. Dr. Marsal has received grants from the Healthcare Region of Southern Sweden, Skane University Hospital, and the Swedish government; grants and personal fees from Abbvie, Ferring, Hospira; and\u00a0personal fees from Bristol-Myers Squibb, Takeda and Tillotts. Dr. Lee has received grant and research support from AbbVie, Arena, Atlantic, Celgene, Gilead Sciences, Janssen, Pfizer, Salix, Shield, Takeda, Tetherex, UCB Pharma\u00a0and has performed consulting for Arena, Celgene, Celltrion Healthcare, Cornerstones, Eli Lilly and Company, Janssen, Mesoblast, Pfizer, Salix, Takeda, and\u00a0UCB Pharma. Dr. Fleisher has served on the\u00a0speaker bureau for Janssen and Takeda. Drs. Korelitz, Frado, and Parian have nothing\u00a0to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"A written informed consent was obtained from patient cases 1, 2, 3, 4, 5, 6, and 8. Case 7 was de-identified and was in compliance with University of Washington Medical Center\u2019s IRB, which does not require an informed consent for single case reports of de-identified patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}